Amivantamab plus lazertinib vs osimertinib in first-line egfr-mutant advanced non-small cell lung cancer

Introduction Thefirst line treatment landscape for patients with NSCLC harboring sensitizing EGFRmutations is rapidly evolving. Initially, osimertinib was the one and onlyoption over earlier generation EGFR inhibitors based on the positive PFS and OSresults from the FLAURA study.